Related Experiment Video

Updated: Jul 4, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.7K

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy

Lu-Qi Cao1,2, Haidong Sun3, Yuhao Xie2

  • 1Institute for Biotechnology, St. John's University, Queens, NY, United States.

Frontiers in Pharmacology
|February 8, 2024
PubMed

Insights

This review covers HR+/HER2- breast cancer, a major subtype. It details epidemiology, classification, and current treatments like targeted and endocrine therapies, including clinical trial updates.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Breast cancer is a significant global health threat, with distinct subtypes.
  • HR+/HER2- breast cancer is a prevalent subtype requiring focused research and treatment strategies.

Purpose of the Study:

  • To review the epidemiology and classification of HR+/HER2- breast cancer.
  • To discuss current and emerging treatment modalities for HR+/HER2- breast cancer.

Main Methods:

  • Literature review of current epidemiological data.
  • Analysis of treatment strategies including targeted therapy, endocrine therapy, and immunotherapy.
  • Inclusion of completed and ongoing clinical trial data.

Main Results:

  • Summary of HR+/HER2- breast cancer prevalence and classification.
  • Detailed discussion on mechanisms of action for targeted and endocrine therapies.
  • Overview of drug synergy and clinical trial outcomes.

Conclusions:

  • HR+/HER2- breast cancer management involves a multi-faceted approach.
  • Ongoing research and clinical trials are crucial for advancing treatment efficacy and patient outcomes.
Keywords:
CDK4/6 inhibitorHR+/HER2-breast cancerPI3K inhibitorSERDSERMclinical trial

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

10.5K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K